COVID-19 Pandemic Clinical Trial
Official title:
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Adults Who is COVID-19 naïve or Had Previous COVID-19 Infection or Completed Inactivated or mRNA COVID-19 Vaccination.
This is a Phase I, open label, dose-escalation study of three dose levels of the SARS-CoV-2 spike antigen administered intramuscularly (IM) in combination with a fixed dosage of PIKA adjuvant vaccine to evaluate the safety, tolerability, and immunogenicity of PIKA COVID-19 vaccine candidate in healthy individuals aged 18 years and above. The study will comprise of two arms. Arm A will include subjects who never been infected with COVID-19 or with a history of COVID-19 infection for not less than 6 months prior to study participation and Arm B will include subjects who will be receiving PIKA vaccine as a booster vaccination dose to COVID-19 primary vaccination of inactivated or mRNA Covid 19 vaccines.
This is a Phase I, open label, dose-escalation study of three dose levels of the SARS-CoV-2 spike antigen administered intramuscularly (IM) in combination with a fixed dosage of PIKA adjuvant vaccine to evaluate the safety, tolerability, and immunogenicity of PIKA COVID-19 vaccine candidate in healthy individuals aged 18 years and above. The study will comprise of two arms. Arm A will include subjects who had never been infected with COVID-19 or with a history of COVID-19 infection for not less than 6 months prior to study participation and Arm B will include subjects who will be receiving PIKA vaccine as a booster vaccination dose to COVID-19 primary vaccination of inactivated or mRNA Covid 19 vaccines. Arm A: There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. A total of 45 subjects will be enrolled in Arm A. Subjects in Group 1-3 will receive two doses of PIKA COVID-19 vaccine via IM administration on Days 0 and 7. Fifteen eligible subjects in each dose group. Arm B: There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. A total of 90 subjects will be enrolled in Arm B which will be divided into Arm B1 (45 subjects) and Arm B2 (45 subjects). Arm B1 will enroll subjects who received Inactivated vaccines and will comprise of 15 subjects per dose (45 subjects). Arm B2 will enroll subjects who received mRNA vaccines and will comprise of 15 subjects per dose (45 subjects). Subjects in Group 1-3 of Arm B1 and Arm B2 will receive one booster dose of PIKA COVID-19 vaccine via IM administration on Days 0. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05197634 -
The Impact of Covid-19 Pandemic On The Children With Autism Spectrum Disorder
|
||
| Recruiting |
NCT05918939 -
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
|
Early Phase 1 | |
| Completed |
NCT05383560 -
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
|
Phase 2 | |
| Active, not recruiting |
NCT05125874 -
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
|
N/A | |
| Completed |
NCT05517148 -
Effects of an Immersive Virtual Reality Intervention Combined With Mindfulness-based Stress Reduction
|
N/A | |
| Completed |
NCT05552989 -
Towards Better Preparedness for Future Catastrophes - Local Lessons-learned From COVID-19
|
||
| Completed |
NCT05543551 -
Effects of Diagrammatic Breathing With and Without Resistance in Post Covid Patients on ADLs
|
N/A | |
| Active, not recruiting |
NCT06272253 -
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
|
Early Phase 1 | |
| Active, not recruiting |
NCT05585567 -
A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5
|
Early Phase 1 | |
| Not yet recruiting |
NCT05381883 -
Mental Health of Professionals of the Silver Economy of New Aquitaine : Online Survey of Accommodation Establishments for Old People and Home Assistance Establishments
|
N/A | |
| Active, not recruiting |
NCT05582746 -
COVID-19 Testing and Vaccine Literacy for Women With Criminal Legal System Involvement
|
N/A | |
| Recruiting |
NCT05062681 -
RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow
|
Phase 4 | |
| Completed |
NCT04697030 -
Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan
|
||
| Active, not recruiting |
NCT05419167 -
STEP-COVID: A Program for Pregnant Women During the SARS-CoV-2 Pandemic
|
Phase 1 | |
| Completed |
NCT06435390 -
Coronavirus Disease 2019 (COVID-19) Pandemic on the Oral Hygiene Status of Children
|
||
| Terminated |
NCT05553964 -
SARS-CoV-2 OTC At Home Test
|
N/A | |
| Completed |
NCT05596032 -
Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2
|
||
| Completed |
NCT05583812 -
A Study of FB2001 for Inhalation in Healthy Chinese Adults
|
Phase 1 | |
| Completed |
NCT05844410 -
Evaluation of Corticosteroids Use and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Study
|
||
| Completed |
NCT05123573 -
Self-Perceived in Medical Students Undergoing Distance Learning
|